Risk factor
Negligible price volatility
Profitability factor
Overvalued vs peers
About
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Target Price
The average target price of LONN.SW is 712 and suggests 32% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell